Skip to main content
Premium Trial:

Request an Annual Quote

Maxing Out On Buzzwords -- We Feel Your Pain

Beware of buzzwords when investing in a new technology, says Derek Lowe at In the Pipeline. He makes fun of an announcement released earlier this year by Primegen, saying that they used carbon nanotubes to reprogram stem cells. Though both are hot fields, they're also still very new. "So what are the odds of getting them to work together? Not as good as the odds that someone thought the combination would make a good press release, I'm afraid," he says. "A good rule to follow: hold onto your wallet when two exciting, complicated fields of research are combined."

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.